FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W35788239> ?p ?o ?g. }

• W35788239 endingPage "248" @default.
• W35788239 startingPage "243" @default.
• W35788239 abstract "Between 1987–1990, 612 patients received high-dose continuous intravenous interleukin-2 (IL-2) in phase II clinical trials of the National Biotherapy Study Group (NBSG). The purpose of this analysis was to determine the long-term survival rates associated with such therapy and the correlation, if any, between objective tumor response, and survival. Patients who are known to have survived at least 3 years or more were identified. Actual and actuarial survival rates were determined for various malignancies and by tumor response. At least 37 (6.0%) survived ≥ 3 years from the initiation of IL-2 therapy, and it is possible the 3—year survival rate is as high as 20%. This included 14/168 (8%) of patients with renal cell carcinoma, 10/175 (6%) melanoma, 2/51 (4%) lung cancer, 0/61 colorectal. 0/36 breast, 1/17 sarcoma, 1/14 pancreas, 1/19 ovary, 3/11 lymphoma, 2 adenocystic carcinomas, 2 carcinoid, and one Hodgkin's disease. Four hundred ninety-one of 612 (80%) are known to have died, 121 were still alive at the time of the last follow-up. Median survival was 7.9 months. Among 547 evaluable patients, there were eight complete responses (CR) and 42 partial responses (PR), for an objective response rate of 9%. An additional 32 patients had mixed or minimal responses (MR) for a total response rate of 15%. The 3-year survival rates were 25% for CR, 17% for PR, 16% for MR, 8% for stable disease (SD), and 2% for patients with progressive disease (PD). Responders made up a higher proportion of patients who survived ≥ 3 years than of patients who survived ≤ 3 years (14/37 = 38% vs 68/500 = 14%; p <.0001, X2). A higher proportion ofresponders survived ≥ 3 years than non-responders (14/82 = 17%vs 23/230 = 4%,p<.0001, X2). Patients with CR PR, or MR had a ≥ 3-year survival rate (14/82 = 17%) than patients who had SD (20/249 = 8%; p =.02, x2, who in turn had a ≥ 3-year survival rate that was greater than patients who had PD (3/206 = 2%;p =.001, X2). For individual trials in which 10 or more patients were enrolled, the percentage of patients surviving ≥ 3 years ranged between 4%> and 8%. We conclude that in the setting of IL-2 therapy for metastatic cancer, the probability of surviving ≥ 3 years was approximately 12 times greater for responders, and five times greater for patients with SD; as compared to patients who had PD. Furthermore, despite diagnoses of metastatic cancer, often in settings in which disease had been refractory to standard therapy there was an actual 3-year survival rate of at least 6% to 8% for patients with metastatic melanoma and renal cell carcinoma." @default.
• W35788239 created "2016-06-24" @default.
• W35788239 creator A5005033200 @default.
• W35788239 creator A5010208681 @default.
• W35788239 creator A5013377891 @default.
• W35788239 creator A5038399837 @default.
• W35788239 creator A5085906072 @default.
• W35788239 date "1997-08-01" @default.
• W35788239 modified "2023-09-25" @default.
• W35788239 title "Long-term Survival after Continuous Infusion Interleukin-2" @default.
• W35788239 cites W1939353013 @default.
• W35788239 cites W1965586355 @default.
• W35788239 cites W2013411992 @default.
• W35788239 cites W2065393730 @default.
• W35788239 cites W2123914905 @default.
• W35788239 cites W2160806636 @default.
• W35788239 cites W2270697554 @default.
• W35788239 cites W2326245275 @default.
• W35788239 doi "https://doi.org/10.1089/cbr.1997.12.243" @default.
• W35788239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10851471" @default.
• W35788239 hasPublicationYear "1997" @default.
• W35788239 type Work @default.
• W35788239 sameAs 35788239 @default.
• W35788239 citedByCount "18" @default.
• W35788239 countsByYear W357882392012 @default.
• W35788239 countsByYear W357882392013 @default.
• W35788239 crossrefType "journal-article" @default.
• W35788239 hasAuthorship W35788239A5005033200 @default.
• W35788239 hasAuthorship W35788239A5010208681 @default.
• W35788239 hasAuthorship W35788239A5013377891 @default.
• W35788239 hasAuthorship W35788239A5038399837 @default.
• W35788239 hasAuthorship W35788239A5085906072 @default.
• W35788239 hasConcept C121608353 @default.
• W35788239 hasConcept C126322002 @default.
• W35788239 hasConcept C141071460 @default.
• W35788239 hasConcept C143998085 @default.
• W35788239 hasConcept C2776283816 @default.
• W35788239 hasConcept C2776694085 @default.
• W35788239 hasConcept C2777472916 @default.
• W35788239 hasConcept C2777546739 @default.
• W35788239 hasConcept C2777658100 @default.
• W35788239 hasConcept C2778822529 @default.
• W35788239 hasConcept C2779338263 @default.
• W35788239 hasConcept C502942594 @default.
• W35788239 hasConcept C509974204 @default.
• W35788239 hasConcept C71924100 @default.
• W35788239 hasConcept C90924648 @default.
• W35788239 hasConceptScore W35788239C121608353 @default.
• W35788239 hasConceptScore W35788239C126322002 @default.
• W35788239 hasConceptScore W35788239C141071460 @default.
• W35788239 hasConceptScore W35788239C143998085 @default.
• W35788239 hasConceptScore W35788239C2776283816 @default.
• W35788239 hasConceptScore W35788239C2776694085 @default.
• W35788239 hasConceptScore W35788239C2777472916 @default.
• W35788239 hasConceptScore W35788239C2777546739 @default.
• W35788239 hasConceptScore W35788239C2777658100 @default.
• W35788239 hasConceptScore W35788239C2778822529 @default.
• W35788239 hasConceptScore W35788239C2779338263 @default.
• W35788239 hasConceptScore W35788239C502942594 @default.
• W35788239 hasConceptScore W35788239C509974204 @default.
• W35788239 hasConceptScore W35788239C71924100 @default.
• W35788239 hasConceptScore W35788239C90924648 @default.
• W35788239 hasIssue "4" @default.
• W35788239 hasLocation W357882391 @default.
• W35788239 hasLocation W357882392 @default.
• W35788239 hasOpenAccess W35788239 @default.
• W35788239 hasPrimaryLocation W357882391 @default.
• W35788239 hasRelatedWork W2335858412 @default.
• W35788239 hasRelatedWork W2349377541 @default.
• W35788239 hasRelatedWork W2377363598 @default.
• W35788239 hasRelatedWork W2387577256 @default.
• W35788239 hasRelatedWork W2387690194 @default.
• W35788239 hasRelatedWork W2389930763 @default.
• W35788239 hasRelatedWork W2401890101 @default.
• W35788239 hasRelatedWork W2404042595 @default.
• W35788239 hasRelatedWork W2416632858 @default.
• W35788239 hasRelatedWork W2441050612 @default.
• W35788239 hasVolume "12" @default.
• W35788239 isParatext "false" @default.
• W35788239 isRetracted "false" @default.
• W35788239 magId "35788239" @default.
• W35788239 workType "article" @default.